Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optional continuation of double-blind CellCept treatment after protocol WX17798 in myasthenia gravis
2005-000343-28Phase 3Completed
- Sponsor
- Aspreva Pharmaceuticals
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of mycophenolate mofetil in myasthenia gravis (MG) (2 arms), sponsored by Aspreva Pharmaceuticals. Primary endpoint: Safety assessments. Started May 2005; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2005-000343-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000343-28.